Juvion’s vision is to redefine aging biology. We aim to prove that age-related loss of movement and memory is driven by weakening cell communication in the nervous system, and that it can be restored with the right compounds. Our focus is strengthening neuron-to-muscle signaling for mobility and neuron-to-neuron signaling for memory and cognition. We are building a high-throughput in vivo discovery system powered by machine vision and real aging biology data, enabling rapid testing of hundreads of compounds and deep real time tracking across life stages. Our core models and assays remain fully protected, ensuring a unique and defensible class of Juvion compounds. Juvion001 is our first step toward therapies that restore strength, mobility, and preserve memory.
Three Swiss startups selected for the Digital Health Accelerator (startupticker.ch)
Venture Leaders Biotech 2025 connects Swiss science with the US biotech market (venturelab.swiss)
MassChallenge Switzerland presents 2025 cohort (startupticker.ch)
Juvion Health Sciences: The Venture Leader Biotech shaping aging therapeutics (venturelab.swiss)
Venture Leaders Biotech 2025 kick off at Swiss Biotech Day ahead of Boston roadshow (venturelab.swiss)
Tech innovators of tomorrow face off at Startup Champions Seed Night 2025 (venturelab.swiss)
Venture Leaders Biotech 2025 cohort revealed (startupticker.ch)
Venture Leaders Biotech 2025: 10 innovative startups selected for Boston roadshow (venturelab.swiss)
IMD Startup competition announces 27th edition winners (startupticker.ch)
Juvion Health Sciences and Neuria win over FIT Funding (startupticker.ch)
Docadom, HireUp, Juvion Life Sciences et Moussse accélérées par GENILEM (startupticker.ch)
Manufacturing JUV-001 for Pilot market entry
Preclinical validation and toxicology analysis
Transformation of the Juvion platform into a fully automated system – Transition from academia to industry level.
Identification of first lead compound-JUV-001
Innosuisse initial coaching